Francesco Locatelli

Dr. Francesco Locatelli

Department of Nephrology and Dialysis, Alessando Manzoni Hospital, Lecco, Italy
orcid

Research Focus & Metrics

Academic Career Length

59Years (1968-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Closed access
HHHiddo J L Heerspink
Hiddo J L Heerspink
TGTom Greene
Tom Greene
HTHocine Tighiouart
Hocine Tighiouart
RGRon T Gansevoort
Ron T Gansevoort
JCJosef Coresh
Josef Coresh
WKWilliam Keane
William Keane

1 April 2003 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
TBTomas Berl
Tomas Berl
LHLawrence G. Hunsicker
Lawrence G. Hunsicker
JLJulia B. Lewis
Julia B. Lewis
MPMarc A. Pfeffer
Marc A. Pfeffer
JPJerome G. Porush
Jerome G. Porush
FGfor the Collaborative Study Group*
for the Collaborative Study Group*
Patients with diabetes have increased risk for adverse cardiovascular events. Angiotensin-converting enzyme inhibitors are protective in type 1 diabetes. However, no definitive studies have examined the use of angiotensin-receptor blockers in patients with type 2 diabetes and overt nephropathy. The primary outcomes of the Irbesartan Diabetic Nephropathy Trial were doubling of serum creatinine levels, end-stage renal disease, and death from any cause. To compare rates of cardiovascular events among patients with type 2 diabetic nephropathy who received conventional antihypertensive therapy with an angiotensin-receptor blocker (irbesartan) or a calcium-channel blocker (amlodipine), or placebo. Randomized double-blind, placebo-controlled trial with a median follow-up of 2.6 years. A time event analysis was used. 209 centers in the Americas, Europe, Israel, and Australasia. 1715 adults with type 2 diabetic nephropathy and hypertension; serum creatinine levels of 89 mol/L (1.0 mg/dL) to 266 mol/L (3.0 mg/dL) in women and 106 mol/L (1.2 mg/dL) to 266 mol/L (3.0 mg/dL) in men; and urinary protein excretion rates of at least 900 mg/d. Treatment with irbesartan, amlodipine, or placebo. Time to cardiovascular death, myocardial infarction, congestive heart failure, strokes, and coronary revascularization. The three groups were not statistically different in the composite of cardiovascular events. Among the components of the composite, there was a trend toward a decrease in strokes in patients receiving amlodipine versus those receiving placebo (hazard ratio, 0.65 [95% CI, 0.35 to 1.22]; P = 0.18). Likewise, patients receiving amlodipine had a significantly lower rate of myocardial infarction when compared with placebo recipients (hazard ratio, 0.58 [CI, 0.37 to 0.92]; P = 0.02). In contrast, patients receiving irbesartan had a significantly lower incidence of congestive heart failure when compared with placebo recipients (hazard ratio, 0.72 [CI, 0.52 to 1.00]; P = 0.048) or amlodipine recipients (hazard ratio, 0.65 [CI, 0.48 to 0.87]; P = 0.004). The composite cardiovascular event rate did not differ in patients with type 2 diabetes and overt nephropathy treated with irbesartan, amlodipine, or placebo in addition to conventional antihypertensive therapy. *For members of the Collaborative Study Group, see the Appendix.

1 January 2016 in Kidney International
Verified
Journal Article
Closed access
PDF file
SBSean J. Barbour
Sean J. Barbour
GEGabriela Espino-Hernandez
Gabriela Espino-Hernandez
HRHeather N. Reich
Heather N. Reich
RCRosanna Coppo
Rosanna Coppo
IRIan S.D. Roberts
Ian S.D. Roberts
EIE. Ioachim
E. Ioachim

1 June 2021 in Kidney International
Verified
Journal Article
Open access
JBJodie L. Babitt
Jodie L. Babitt
MEMichele F. Eisenga
Michele F. Eisenga
VHVolker H. Haase
Volker H. Haase
AKAbhijit V. Kshirsagar
Abhijit V. Kshirsagar
ALAdeera Levin
Adeera Levin
MWMyles Wolf
Myles Wolf
In chronic kidney disease, anemia and disordered iron homeostasis are prevalent and associated with significant adverse consequences. In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) issued an anemia guideline for managing the diagnosis, evaluation, and treatment of anemia in chronic kidney disease. Since then, new data have accrued from basic research, epidemiological studies, and randomized trials that warrant a re-examination of previous recommendations. Therefore, in 2019, KDIGO decided to convene 2 Controversies Conferences to review the latest evidence, explore new and ongoing controversies, assess change implications for the current KDIGO anemia guideline, and propose a research agenda. The first conference, described here, focused mainly on iron-related issues, including the contribution of disordered iron homeostasis to the anemia of chronic kidney disease, diagnostic challenges, available and emerging iron therapies, treatment targets, and patient outcomes. The second conference will discuss issues more specifically related to erythropoiesis-stimulating agents, including epoetins, and hypoxia-inducible factor-prolyl hydroxylase inhibitors. Here we provide a concise overview of the consensus points and controversies resulting from the first conference and prioritize key questions that need to be answered by future research.

1 February 2017 in American Journal of Kidney Diseases
Verified
Journal Article
Open access
PDF file
AKAngelo Karaboyas
Angelo Karaboyas
JZJarcy Zee
Jarcy Zee
SBSteven M. Brunelli
Steven M. Brunelli
LULen Usvyat
Len Usvyat
DWDaniel E. Weiner
Daniel E. Weiner
FTFrancesca Tentori
Francesca Tentori
Background Sudden death is a leading cause of death in patients on maintenance hemodialysis therapy. During hemodialysis sessions, the gradient between serum and dialysate levels results in rapid electrolyte shifts, which may contribute to arrhythmias and sudden death. Controversies exist about the optimal electrolyte concentration in the dialysate; specifically, it is unclear whether patient outcomes differ among those treated with a dialysate potassium concentration of 3 mEq/L compared to 2 mEq/L. Study Design Prospective cohort study. Setting & Participants 55,183 patients from 20 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS) phases 1 to 5 (1996-2015). Predictor Dialysate potassium concentration at study entry. Outcomes Cox regression was used to estimate the association between dialysate potassium concentration and both all-cause mortality and an arrhythmia composite outcome (arrhythmia-related hospitalization or sudden death), adjusting for potential confounders. Results During a median follow-up of 16.5 months, 24% of patients died and 7% had an arrhythmia composite outcome. No meaningful difference in clinical outcomes was observed for patients treated with a dialysate potassium concentration of 3 versus 2 mEq/L (adjusted HRs were 0.96 [95% CI, 0.91-1.01] for mortality and 0.98 [95% CI, 0.88-1.08] for arrhythmia composite). Results were similar across predialysis serum potassium levels. As in prior studies, higher serum potassium level was associated with adverse outcomes. However, dialysate potassium concentration had only minimal impact on serum potassium level measured predialysis (+0.09 [95% CI, 0.05-0.14] mEq/L serum potassium per 1 mEq/L greater dialysate potassium concentration). Limitations Data were not available for delivered (vs prescribed) dialysate potassium concentration and postdialysis serum potassium level; possible unmeasured confounding. Conclusions In combination, these results suggest that approaches other than altering dialysate potassium concentration (eg, education on dietary potassium sources and prescription of potassium-binding medications) may merit further attention to reduce risks associated with high serum potassium levels.

1 November 2008 in Kidney International
Verified
Journal Article
Closed access
Francesco LocatelliFrancesco Locatelli
Francesco Locatelli
ANAllen R. Nissenson
Allen R. Nissenson
BBBrendan J. Barrett
Brendan J. Barrett
RWRowan G. Walker
Rowan G. Walker
DWDavid C. Wheeler
David C. Wheeler
GEGarabed Eknoyan
Garabed Eknoyan